Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated study (cwCLL-001 study)

会议时间：2023-12-20 18:00:00